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Abstract
The risks and benefits of cytoreductive surgery combined with hyperthermic
intraperitoneal chemotherapy (CS/HIPEC) continue to be debated by the
oncology community. A retrospective analysis of contemporary data (2003–
2011) was performed to provide objective information regarding surgical
morbidity, mortality, and survival for patients undergoing CS/HIPEC at a com-
prehensive cancer center. While procedure-associated morbidity was compara-
ble to other major surgical oncology procedures, there was no operative or 30-
day mortality and 60-day mortality was 2.7%. Increasing numbers of bowel
resections were found to correlate to an increased incidence of deep surgical
site infections (including abscess and enterocutaneous fistula) and need for
reoperation which was in turn associated with a decreased overall survival (OS)
and progression-free survival (PFS). Five-year OS rates varied by site of tumor
origin and histology (disseminated peritoneal adenomucinosis [91.3%],
Mesothelioma [80.8%], Appendiceal Adenocarcinoma [38.7%], and Colorectal
Adenocarcinoma [38.2%]). With an acceptable morbidity and mortality rate,
CS/HIPEC should be included as an effective treatment modality in the multi-
disciplinary care of select patients with peritoneal metastases.
Introduction
Historically, peritoneal carcinomatosis (PC) from adeno-
carcinomas of nongynecologic origin was considered vir-
tually incurable with an average life expectancy of
6 months [1, 2]. Even with the best systemic chemo-
therapy regimens, current median overall survival (OS)
and disease-free survival (DFS) are only 20 and
10 months, respectively [3–5]. The role of surgery for PC
has slowly evolved from palliation to potential curative
intent. Attempting to remove all visible tumor deposits,
“surgical cytoreduction” was first reported in the 1930s
for ovarian cancer and eventually became an accepted
therapy with proven survival benefit [6–9]. Several dec-
ades later, the clinical application of cytoreduction for
nongynecologic malignancies and the addition of concur-
rent hyperthermic intraperitoneal chemotherapy (HIPEC)
for the purpose of eliminating remnant microscopic dis-
ease was described [10]. More recently, the use of
cytoreductive surgery (CS)/HIPEC for nongynecologic
malignancies has expanded and is based upon the concept
that carcinomatosis is a locoregional phenomenon requir-
ing a locoregional treatment [11].
The risks and benefits of CS/HIPEC for nongynecologic
malignancies continue to be vigorously debated in the
oncology community despite a growing body of evidence
regarding clinical efficacy. Eleven Phase II studies demon-
strate a 5-year OS rate ranging from 25% to 47% for
colorectal PC treated by cytoreduction and HIPEC, which
prompted a Phase III randomized controlled study in this
population [12]. The standard therapy group received
palliative surgery and “best systemic therapy” consisting
of fluorouracil and leucovorin, while the experimental
group underwent maximal cytoreduction and HIPEC
followed by “best systemic therapy”. A significant benefit
in OS favoring CS/HIPEC compared to standard therapy
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alone, 21.6 versus 12.6 months, was reported. Recently
updated data shows a 6-year survival rate of 5% in the
standard arm versus 20% in the CS/HIPEC arm [13].
Five-year survival for patients who achieved a complete
cytoreduction (CCR0) was an astounding 45%, in con-
trast to incomplete cytoreduction patients whose median
survival was <1 year. Regardless of potential selection
bias, these reports collectively suggest that a cohort of
carcinomatosis patients truly benefit from this approach
and that current systemic chemotherapy regimens are still
unlikely to match the observed differences in survival or
long-term cures generated by CS/HIPEC [3, 14]. How-
ever, morbidity remains a concern as many studies report
a 27–56% perioperative complication rate [15]. The Phase
III study published in 2003 had an 8% mortality rate with
some centers reporting mortality up to 11% [12, 15].
To determine more contemporary rates of morbidity
and mortality associated with CS/HIPEC, we have
reviewed our institutional experience with this procedure
over a recent 8-year period. Our goal is to provide objec-
tive data regarding the safety and efficacy of performing
cytoreduction and HIPEC in the setting of a comprehen-
sive cancer center.
Material and Methods
Patients
All patients who underwent CS/HIPEC at Roswell Park
Cancer Institute (RPCI) from 2003–2011 were retrospec-
tively reviewed. Institutional ethics approval for this
review was obtained. Strict and uniform inclusion criteria
for surgical eligibility included: disease localized to the
peritoneal cavity, no distant organ metastases (including
the liver or lung), and a baseline functional status of East-
ern Cooperative Oncology Group (ECOG) 2. In an
attempt to define factors associated with the morbidity of
the CS/HIPEC procedure, all patients were included for
analysis. Patients were evaluated retrospectively from their
date of CS/HIPEC at RPCI to an end point consisting of
either date of last follow-up or death. Patients that under-
went surgical exploration and were not deemed a candi-
date for CS/HIPEC were excluded from this study, as
were patients only undergoing CS without HIPEC.
Surgery
All CS/HIPEC surgeries were performed by two surgeons,
using the same technique. Through a generous midline
laparotomy incision, inspection of the abdomen was per-
formed to determine the feasibility of obtaining a CCR.
Disease involving the porta hepatis, duodenum, major
vascular structures, or an extent of small bowel serosa
involvement that would preclude a CCR0 did not
undergo CS/HIPEC. Patients who were deemed appropri-
ate for CS underwent greater and lesser omentectomy,
resection of the falciform ligament and ligamentum teres,
resection of prior abdominal scars, and bilateral salpingo-
oophorectomy in female patients was always performed.
Additional sites of gross disease were cytoreduced as indi-
cated by visceral resections, peritoneal stripping, and/or
fulguration or argon beam coagulation. A CCR0 was clas-
sified as those patients who had all visible tumor nodules
resected, with no further nodules or implants >2 mm. An
incomplete cytoreduction (CCR1 or greater) was consid-
ered to include patients that had residual tumor nodules
after cytoreduction >2 mm.
Once CS was completed, closed HIPEC was initiated by
placing a single outflow cannula within the anterior pelvis
and two inflow cannulae at the base of the hemi-
diaphragms. The cannulae exited through the midline
incision, which was temporarily closed with a running
suture. Temperature probes were inserted into the cannu-
lae. Three liters of a balanced saline solution were instilled
into the peritoneum via the HIPEC circuit, air was evacu-
ated from the circuit, and flow and warming of the fluid
commenced. When the inflow and outflow temperatures
reached ~41°, HIPEC was performed for 60–120 min. All
patients received 30 mg of Mitomycin C (MMC) via
HIPEC. An additional 10 mg MMC was administered at
60 min. The minimal acceptable flow rate was 500 mL/
min with no limit on the maximum achievable flow rate.
At the end of HIPEC, the chemotherapy was evacuated
and the abdominal cavity irrigated with 3 L of crystalloid
via the closed perfusion circuit. Upon reopening of the
abdominal cavity, the viscera were inspected for any
potential injury associated with the HIPEC. Bowel ana-
stomoses were performed at this time. The need for a
diverting ostomy was at the discretion of the surgeon.
Placement of Seprafilm (Sanofi US, Bridgewater, NJ) in
the midline was followed by fascial closure. Prior to skin
closure with staples, a closed suction drain was placed in
the subcutaneous tissues to address any HIPEC-induced
fat necrosis. Chest tubes and total parenteral nutrition
(TPN) were not routinely utilized. All patients went to
the intensive care unit (ICU) immediately postoperatively.
Demographics
Baseline patient characteristics were divided into categori-
cal and continuous measures. Categorical measures
included gender, primary tumor location, histology, pre-
operative chemotherapy use, ostomy creation at time of
HIPEC, and completeness of cytoreduction. These were
reported as frequencies and relative frequencies. Continu-
ous measures included age, postoperative ICU stay (days),
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total length of hospital stay (days), estimated blood loss,
number of bowel resections, and anastomoses with means
and standard deviations.
Primary tumor location was classified as colorectal,
appendix, or other (small bowel, gastric, ovarian, pancre-
atic, primary peritoneal). Tumor histology was classified
as colorectal adenocarcinoma, appendiceal adeno-
carcinoma, disseminated peritoneal adenomucinosis
(DPAM), mesothelioma, or other (adenocarcinoid, sar-
coma, ovarian serous papillary).
Complications
Complications were recorded as binary variables and
reported as frequencies and relative frequencies. These
included superficial surgical site infection, deep surgical
site infection (anastomotic leak, enterocutaneous fistula
[ECF], or abscess), pulmonary (pneumonia, pleural effu-
sion), cardiac (myocardial infarction, arrhythmia), renal
(renal failure), urinary tract infection (UTI), venous
thromboembolism (deep vein thrombosis, pulmonary
embolus, portal vein thrombosis), gastrointestinal (GI;
pancreatitis, ascites, ileus, clostridium difficile colitis, TPN
requirement), hematologic (anemia, bleeding), neutrope-
nia (absolute neutrophil count <1000), and other (line
sepsis, bacteremia, lower extremity compartment syn-
drome). Given the anticipated length of stay (LOS) we
cite for our patients being 14 days or less, LOS >14 days
was used as a surrogate for a complicated postoperative
course in this cohort even if no defined complication had
occurred.
Any association between baseline patient characteristics
and incidence of postoperative complication were assessed
using logistic regression modeling. Patient characteristic
was listed as the independent variable and complication
was the dependent variable. From these models, odds
ratios were obtained with a 95% confidence interval. A
P-value of <0.05 indicated a statistically significant rela-
tionship.
Survival
OS and progression-free survival (PFS) were generated
using Kaplan–Meier method. Kaplan–Meier curves were
also used to show associations with variables and
compared with Log Rank tests.
Results
A total of 112 patients underwent surgical exploration
and CS/HIPEC (Table 1). The median patient age was
53 years and the majority of patients were female
(59.8%). Median operative time was 12 h and median
estimated blood loss was 200 mL. The median number of
bowel resections and anastomoses was 1 with the majority
of patients (90.2%) avoiding the creation of an ostomy at
the time of CS/HIPEC. The median length of ICU and
overall hospital stay were 1 and 12 days, respectively.
There were no operative or 30-day mortalities and the
60-day mortality rate was 2.7%.
The most common histology encountered was adeno-
carcinoma, with tumors of colorectal origin being the
most common indication for CS/HIPEC. Nearly half of
the patients received some form of preoperative chemo-
therapy. The majority of patients (74%) received the
anticipated full dose of MMC during HIPEC with dose
reduction in the remainder due to extensive preoperative
chemotherapy exposure or body habitus as determined by
Table 1. Characteristics of patients undergoing CS/HIPEC.
Demographic data
Age Median years (range) 53 (16–79)
Gender Male (%) 45 (40.2%)
Primary tumor site Colorectal (%) 38 (33.9%)
Appendix (%) 51 (45.5%)
Other1(%) 23 (20.5%)
Tumor histology Colorectal
adenocarcinoma (%)
38 (33.9%)
Appendiceal
adenocarcinoma (%)
24 (21.4%)
DPAM2(%) 27 (24.1%)
Peritoneal
mesothelioma (%)
11 (9.8%)
Other3(%) 12 (10.7%)
Preoperative
chemotherapy
(%) 51 (45.5%)
Operative data
Ostomy (%) 11 (9.8%)
Bowel resections Median (range) 1 (0–3)
0 40 (35.7%)
1 42 (37.5%)
2 23 (20.5%)
3 7 (6.3%)
GI anastomoses Median (range) 1 (0–3)
Operative time Median hours (range) 12 (6–20)
Estimated blood loss Median mL (range) 200 (0–2500)
Complete cytoreduction (%) 72 (64.3%)
HIPEC dose reduction (%) 29 (25.9%)
Reoperation rate (%) 11 (9.8%)
ICU stay Median days (range) 1 (0–21)
Length of hospital stay Median days (range) 12 (6–122)
Follow-up time Median months (range) 25 (1–80)
DPAM, disseminated peritoneal adenomucinosis; GI, gastrointestinal;
HIPEC, hyperthermic intraperitoneal chemotherapy; ICU, intensive care
unit.
1Includes small bowel, gastric, ovarian, pancreatic, primary peritoneal.
2Disseminated peritoneal adenomucinosis.
3Adenocarcinoid, sarcoma, ovarian serous papillary.
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the operating surgeon. A CCR0 was achieved in the
majority of patients (64.3%). The 35.7% of patients that
did not receive a complete cytoreduction (CCR1 or
greater) received HIPEC.
Considering operative morbidity and mortality, super-
ficial surgical site infection was noted most commonly in
15.2% of patients (Table 2). Deep surgical site infections
including anastomotic leak, ECF, and abscess occurred in
10.7% of patients. GI complications not attributed to the
above mentioned deep surgical site infections occurred in
14.3% of patients. The remainder of complications
including cardiac, pulmonary, renal, UTI, venous thrombo-
embolism, hematologic, neutropenia occurred infre-
quently. Directly related to HIPEC, neutropenia occurred
in 6.3% of patients. As a surrogate for morbidity, length
of stay in the hospital (LOS) was >14 days for 24.1% of
patients. Reoperation, either at the time of admission for
CS/HIPEC or within 30 days, was required for 6.3% of
patients due to the need for enteric diversion or hemo-
stasis. Median days to reoperation was 11, with six surgeries
occurring for anastomotic leak, three for incisional infec-
tion/infected mesh, one for bleeding requiring hemostasis,
and one for compartment syndrome of the lower extremity
requiring fasciotomy related to positioning in stirrups.
The potential association between baseline patient
treatment related factors and complications was assessed
using logistic regression modeling (Table 3). Significant
associations were observed between superficial surgical
site infection and placement of an ostomy (P = 0.007).
Prolonged ICU stay was associated with a deep surgical
site infection (P < 0.001), and need for reoperation on
the same admission (P = 0.009). Overall length of hospi-
tal stay was prolonged by a deep surgical site infection
(P = 0.003) and need for reoperation (P = 0.032).
Increasing number of bowel resection was associated with
a deep surgical site infection (P = 0.004) and need for
reoperation (P = 0.006).
OS and PFS were determined for all patients under-
going the CS/HIPEC procedure (Fig. 1). Of the 112
patients, a total of 35 deaths were observed, with a med-
ian survival time of 63.2 months. A total of 55 progres-
sion events, including death or recurrence, were observed,
with a median progression-free time of 22 months. Com-
plications with significant associations with poor survival
were observed between deep surgical site infection and
both OS (P = 0.0001) and PFS (P = 0.0321), and reoper-
ation and both OS (P < 0.0005) and PFS (P < 0.0001)
(Fig. 2).
Regarding site of tumor origin, colorectal patients had
a poorer PFS compared to appendiceal and other sites
(P < 0.001). Adenocarcinoma histology, regardless of site
of origin, was associated with a worse OS (P = 0.025)
and PFS (P < 0.001) compared to other histologies
(Fig. 3). The factors associated with OS and PFS and the
statistical significance of these associations are summa-
rized in Table 4.
Considering complete versus incomplete cytoreduction
for all cases excluding DPAM, Figure 4 indicates a trend
toward better OS in those patients undergoing a CCR,
although this did not reach statistical significance
(P = 0.0659). While this group is heterogeneous in terms
of tumor behavior and prior treatments, the trend toward
CCR appeared to be a predictor of survival regardless of
histology.
Discussion
The results of our analyses imply that the surgical proce-
dure of CS/HIPEC in the contemporary setting can be
Table 2. Operative morbidity and mortality.
Variable n %
Morbidity
Superficial surgical site infection 17 15.2
Deep surgical site infection 12 10.7
Pulmonary complications 4 3.6
Cardiac complications 3 2.7
Renal complications 1 0.9
UTI 5 4.5
Venous thromboembolism 5 4.5
Gastrointestinal complications 16 14.3
Hematologic complications 1 0.9
Neutropenia 7 6.3
Other1 4 3.6
Mortality
30-day mortality 0 0
60-day mortality 3 2.7
Operative mortality 0 0
UTI, urinary tract infection.
1Includes line sepsis, bacteremia, lower extremity compartment
syndrome.
Table 3. Factors related to risk of complication following CS/HIPEC.
Complication Dependent variable
Odds ratio
(95% CI) P-value
Superficial surgical
site infection
Ostomy 6.18 (1.63–23.4) 0.007
Deep surgical
site infection
ICU stay
LOS
# of bowel
resections
1.54 (1.23–2.02)
1.16 (1.05–1.27)
2.79 (1.40–5.56)
<0.001
0.003
0.004
Reoperation ICU stay
LOS
# of bowel
resections
# of anastomoses
1.35 (1.08–1.70)
1.09 (1.01–1.19)
3.65 (1.45–9.16)
4.16 (1.61–10.75)
0.009
0.032
0.006
0.003
ICU, intensive care unit; LOS, length of stay.
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performed safely with minimal postoperative mortality
and acceptable morbidity. These data are consistent with
low morbidity when including surrogates of complica-
tions such as LOS >14 days (24.1% of all patients) and
considering the median ICU (1 day) and overall hospital
stay (12 days). In this cohort, there was no operative
mortality, and the 30- and 60-day mortality was low
compared to other major surgical oncology procedures
[16–18]. The low morbidity and mortality associated with
our series is likely reflective of a strict patient selection,
experienced preoperative staff (radiology, pathology, and
medical oncology), and postoperative ancillary staff (nurs-
ing, respiratory, dietary, and physical therapy). Accord-
ingly, CS/HIPEC has been used at our institution in a
multidisciplinary fashion. Nearly half of the patients in
our series received preoperative chemotherapy suggesting
that CS/HIPEC is viewed as an adjunct, and not a
replacement for systemic therapy in select patients. The
Figure 2. Deep surgical site infection was associated with a reduced 5-year survival from 59.7% of those with no deep surgical site infection
down to 16.4%. Progression-free survival was similarly reduced in patients with deep surgical site infection from 41.3% to 13.6% over 5 years.
Indicative of a serious complication, patients requiring reoperation had similar reductions of 20.8% and 20.3% in 5-year overall survival and
progression-free survival, respectively.
Figure 1. For a mixed population of patients, tumor origin, and tumor histologies, the procedure of cytoreduction and hyperthermic
intraperitoneal chemotherapy (HIPEC) was associated with a median overall survival (OS) of 63.2 months with a 5-year survival rate of 55.2% in
our series. The median progression-free survival (PFS) was 22 months. Cytoreduction/HIPEC as a procedure did not exhibit any prohibitive or
significant procedure-related early mortality in the overall patient population.
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ability to achieve a CCR0 in 64% of patients is also a
reflection of patient selection and a multidisciplinary
approach. Performing these often rigorous procedures
is enhanced by the resources available to a dedicated
comprehensive cancer center and a low mortality and
morbidity should be readily achievable in similar settings.
In our series, deep surgical site infection including
anastomotic leak, ECF, and abscess, was the most serious
Table 4. Survival rates and associated factors following CS/HIPEC.
Five-year
OS rate
Median time1
(95% CL)
Hazard ratio2
(95% CL)
Five-year
PFS rate
Median time1
(95% CL)
Hazard ratio2
(95% CL)
Tumor location
Colon 38.2% 45.2 (30.4, 64.4) 1.000 15.2% 11.5 (6.5, 19.0) 1.000
Appendix 66.6% NR (39.9, NR) 0.42 (0.19, 0.91) 49.8% 37.4 (18.1, NR) 0.35 (0.19, 0.63)
Other 66.2% 68.5 (20.0, NR) 0.66 (0.27, 1.59) 53.9% 68.5 (8.2, NR) 0.34 (0.15, 0.75)
Tumor histology
Colorectal adenocarcinoma 38.2% 45.2 (30.4, 64.4) 1.000 15.2% 11.5 (6.5, 19.0) 1.000
Appendiceal adenocarcinoma 38.7% 39.9 (29.2, NR) 0.78 (0.34, 1.81) 35.2% 18.1 (11.1, NR) 0.58 (0.30, 1.13)
DPAM 91.3% NR (NR, NR) 0.15 (0.03, 0.64) 64.4% NR (37.4, NR) 0.19 (0.08, 0.45)
Mesothelioma 80.8% 68.5 (8.2, NR) 0.39 (0.11, 1.36) 70.7% 68.5 (5.4, NR) 0.21 (0.06, 0.70)
Other 48.0% 26.3 (3.8, NR) 1.30 (0.43, 3.89) 32.0% 21.1 (3.3, NR) 0.52 (0.20, 1.35)
OS, overall survival; PFS, progression-free survival; DPAM, disseminated peritoneal adenomucinosis; NR, not reached.
1Time measured in months.
2Hazard ratio compared to colon (location) or colorectal adenocarcinoma (histology).
Figure 3. The site of tumor origin had a significant influence on survival. Patients with carcinomatosis from a colorectal primary had a 5-year
overall survival of 38.2%, which was significantly lower than appendix origin (66.6%) or other sites (66.2%). The median time to progression
exhibited a similar association to tumor location with colon (11.5 months) being less than appendix (37.4 months) or other sites (68.5 months).
Tumor histology was also associated with 5-year overall survival as adenocarcinoma of either colon (38.2%) or appendiceal (38.7%) doing worse
than disseminated peritoneal adenomucinosis (DPAM) (91.3%), mesothelioma (80.8%), or others (48.0%). A similar pattern was noted for the
median time to progression and progression-free survival for these tumor histologies.
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morbidity, and this occurred in 10.7% of patients. This
appears to be similar to other reported incidences during
CS/HIPEC [19–21]. When present, however, our analyses
suggest that anastomotic leak/ECF is associated with a
lower OS and PFS. These patients often require reopera-
tion for enteric diversion and reoperation itself was asso-
ciated with a lower OS and PFS. A factor linked to a
higher likelihood of deep surgical site infection was the
number of bowel anastomoses. Therefore, the need for an
increasing number of bowel anastomoses, associated with
anastomotic leak/ECF and lower OS and PFS likely
reflects aggressive tumor biology and possibly a surrogate
for extent of disease, which portends a potentially poorer
outcome. While the percentage of patients who received
an ostomy at the time of CS/HIPEC was low (9.8%) in
this series, it is unclear if deep surgical site infections
would have been reduced with diversion.
Inclusive of all tumor origin sites and histologies, the
procedure of CS/HIPEC had an excellent OS (median
63.2 months) and PFS (22 months). The site of primary
tumor origin appeared to greatly influence survival and is
consistent with the previously reported literature [22–25].
Patients whose primary tumor was of colorectal origin
had a decreased median PFS as compared with appendi-
ceal or other tumor site origins. Regarding tumor histol-
ogy, adenocarcinomas of colorectal or appendiceal origin
had the lowest survival compared with DPAM and perito-
neal mesothelioma. Five-year OS rates for patients treated
for adenocarcinomas of colorectal and appendiceal origin
were 38.2 and 38.7 months, respectively. Following treat-
ment, the 5-year OS rate for patients with DPAM was
91.3 and 68.5 months for patients with peritoneal meso-
thelioma. These findings are highly consistent with pub-
lished data regarding outcomes associated with CS/HIPEC
for the various histologies and their associated tumor
biology.
While we believe the current analyses demonstrate the
utility and safety of CS/HIPEC at our center, there are
certain limitations of the study that must be recognized.
First, the study is retrospective in nature and any selec-
tion bias would be difficult to determine. For example,
the patients in this study represent patients who fulfilled
our strict criteria for eligibility for CS/HIPEC, which may
have improved our survival data compared with older
studies. While selection bias remains a possibility, our
results support the notion that having strict eligibility cri-
teria may assist in determining the cohort of patients who
may achieve the maximal benefits of this procedure, and
conversely, those that may not benefit from it. It has been
suggested that CS/HIPEC selects the patients that are
likely to have a good outcome with any therapy. Our
results would strongly argue against this, as almost half of
the patients received preoperative chemotherapy and then
proceeded to CS/HIPEC for either residual or refractory
disease. In the rare patient who clinically and/or radio-
graphically exhibited a complete response to systemic che-
motherapy, CS/HIPEC was still performed as these
patients often exhibit pathology-proven active disease in
the peritoneum found at the time of surgery.
Prognosis and probability of CCR in patients undergo-
ing CS/HIPEC have been shown in a number of studies
to be related to the Peritoneal Cancer Index (PCI), a
reflection of the extent and location of disease noted in
the abdominal cavity upon exploration [26]. Comparing
our current study to other CS/HIPEC series is possible
when considering the completeness of cytoreduction, but
is constrained by our lack of intraoperative PCI scoring.
In our evaluated cohort, a large number of patients were
pretreated with systemic chemotherapy prior to CS/
HIPEC, making the “initial” or true PCI score unknown.
In patients who have received multiple lines of systemic
chemotherapy and have not exhibited the development of
systemic metastases, it is unclear whether PCI scoring at
the time of CS/HIPEC would more accurately predict
survival or outcome compared to the completeness of
cytoreduction.
Figure 4. Despite being a heterogeneous population, completeness of cytoreduction in all patients (excluding DPAM) appeared to be associated
with improved OS, although this did not reach statistical significance (P = 0.0659). PFS was not different in those patients undergoing a complete
cytoreduction as compared with an incomplete cytoreduction. DPAM, disseminated peritoneal adenomucinosis; OS, overall survival; PFS,
progression-free survival.
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Another potential limitation for comparison of OS and
PFS was the lack of comparison to a similar cohort of
patients that received systemic chemotherapy only. Cur-
rently, randomized trials comparing CS/HIPEC to sys-
temic chemotherapy are unlikely to accrue a significant
number of patients for a variety of reasons as recently
demonstrated by ACOSOG Z6091 which was closed for
lack of enrollment (one patient accrued in 2 years, with a
goal of 340) [27, 28]. While the lack of a control arm
may represent a concern for those who view CS/HIPEC
as a complete alternative to systemic chemotherapy, we
readily acknowledge that CS/HIPEC was employed in a
multidisciplinary fashion at our institute, to augment
other therapies provided to these patients. Furthermore,
preoperative and/or postoperative systemic chemotherapy
likely had a major benefit in a significant percentage of
our patients and CS/HIPEC should be viewed as a com-
plementary therapy. Lastly, these single institution results
may not be able to be extrapolated to other treatment
centers. We believe, however, that the utilization of strict
eligibility criteria, a strong multidisciplinary approach,
and experienced support staff is likely to optimize the
outcomes of these patients at similar treatment centers.
In summary, these findings argue against the mis-
conception that the mortality and morbidity associated
with CS/HIPEC is prohibitive as has been recently sug-
gested [27, 29–31]. These results also demonstrate that
CS/HIPEC may be an effective option in patients with PC
from colorectal adenocarcinoma that manifest disease
only within the peritoneal cavity, despite receiving sys-
temic chemotherapy. CS/HIPEC has the potential to offer
significant survival prolongation in select patients.
Patients that require multiple bowel resections and anas-
tomoses during CS/HIPEC may not benefit from this
approach, possibly related to tumor biology, and alterna-
tive strategies should be explored. Continued investiga-
tions into optimal treatment algorithms that include CS/
HIPEC are justified.
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